Explainer: Airway Remodeling in Asthma

Airway remodeling in asthma is not a distant complication but a core driver of disease progression. This explainer examines the mechanisms behind structura…

Airway remodeling in asthma is not a distant complication but a core driver of disease progression. This explainer examines the mechanisms behind structural changes in the airway wall, what current research shows about their trajectory, and how that knowledge could reshape therapeutic strategies in the coming years.

Mechanisms: how remodeling begins and what sustains it

Airway remodeling refers to a constellation of structural alterations in the bronchi and bronchioles, including thickening of the airway walls, subepithelial collagen deposition, smooth muscle hypertrophy, and goblet cell hyperplasia. As of late 2025, studies indicate remodeling can begin early in life and progress despite conventional anti-inflammatory therapy. A longitudinal cohort of children with mild-to-moderate asthma found that by age 10, approximately 60–70% exhibited measurable subepithelial fibrosis on epithelial brushings and imaging markers, correlating with reduced peak expiratory flow (PEF) variability.

Mechanistically, remodeling is driven by chronic injury and repair cycles. Epithelial shedding and eosinophilic inflammation release profibrotic mediators such as transforming growth factor-beta (TGF-β) and platelet-derived growth factor (PDGF), which stimulate fibroblast activation and extracellular matrix (ECM) deposition. In parallel, airway smooth muscle (ASM) layers hypertrophy and hypercontract, narrowing luminal area. Recent single-cell RNA sequencing analyses identify distinct fibroblast phenotypes—myofibroblasts with high COL1A1 and α-smooth muscle actin expression—that sustain ECM remodeling even when eosinophilic inflammation subsides. Animal models using allergen challenge show remodelling persists months after allergen withdrawal, suggesting durable reprogramming of airway mesenchyme rather than transient edema alone.

• Subepithelial fibrosis is present in roughly 40–50% of sputum samples from moderate-severe asthma patients, with collagen type III and VI upregulation observed in bronchoalveolar lavage (BAL) fluid.
• ASM layer thickness increases by about 20–40% in many pediatric cohorts over 2–5 years of follow-up, independent of baseline inflammation intensity.

Inflammation remodeling axis: when anti-inflammatory therapy falls short

Conventional inhaled corticosteroids (ICS) effectively suppress eosinophilic inflammation but have inconsistent effects on structural remodeling. In a 2023 meta-analysis of 20 randomized trials, ICS reduced airway hyperresponsiveness by an average of 15–20% but did not consistently halt thickening of airway walls measured by high-resolution CT (HRCT) and endobronchial biopsies. A parallel finding is that macrolide therapies, while reducing exacerbation rates, show limited impact on remodeling indices over 12–18 months. This disconnect raises urgent questions about the timing and targets of therapy.

Beyond eosinophils, mast cells and neutrophils contribute to remodeling, particularly in severe asthma phenotypes. Neutrophilic inflammation associates with increased ASM mass and goblet cell metaplasia, and neutrophil-derived proteases (e.g., neutrophil elastase) promote ECM degradation that paradoxically triggers fibrotic repair loops. TGF-β remains a central node in many remodeling networks: its activity correlates with airway wall thickness and diminished lung function across longitudinal studies. A 2024 analysis of BAL cytokines reported TGF-β levels remained elevated in patients with persistent remodeling even when airway inflammation scores decreased, suggesting decoupled pathways for inflammation and remodeling in chronic disease stages.

• In a cohort of 400 adults with asthma, patients on high-dose ICS/LABA therapy showed a 12% reduction in exacerbation rate but no significant change in airway wall thickness over 3 years.
• Biomarker panels linking periostin, TGF-β, and YAP/TAZ signaling were predictive of remodeling-related decline in FEV1 over 5 years, independent of symptom scores.

Imaging and histology: tracking the remodeling footprint

Advances in imaging have sharpened our view of remodeling. HRCT yields quantitative metrics of airway wall thickness (AWT), wall area ratio, and lumen area, enabling longitudinal tracking. In a late-2024 multicenter study of 312 adults with asthma, AWT increased by a mean of 12–14% over a 3-year period in subjects with poor baseline control, while those on biologics targeting IL-5 or IL-4Rα displayed smaller, non-significant changes, hinting at a protective effect against remodeling progression. Endobronchial biopsies provide cellular resolution: fibroblast foci, myofibroblast presence, and ECM deposition correlate with spirometric decline and escalations in post-bronchodilator bronchodilator response. A noteworthy finding is that remodeling markers can accompany symptom stability, complicating clinical assessment that relies solely on patient-reported outcomes.

Emerging modalities, such as magnetic resonance imaging with hyperpolarized gases or hyperdense endoscopic mapping, offer noninvasive windows into small-airway remodeling, which is often underappreciated by conventional spirometry. For instance, small-airway conductance measurements have shown declines of approximately 8–15% in a 2-year window for patients with persistent remodeling, even when FEV1 remained within 80–100% of predicted values. This dissociation underscores the need for multi-parameter surveillance in clinical practice.

• Subepithelial thickness on biopsy correlates with reduced peak expiratory flow variability, a marker of airway instability, in over 70% of pediatric cases followed for 4 years.
• Biologics targeting type 2 inflammation show a trend toward stabilizing wall thickening, with average AWT changes near zero in a 1–3 year horizon for a subset of responders.

Biologics and disease modification: what the data suggest about remodeling impact

Biologic therapies—interleukin-5 (IL-5) antagonists, IL-4/13 blockade, and IgE inhibitors—have reshaped outcomes for many patients with severe asthma. Their impact on remodeling, however, is variable and increasingly nuanced. A 2023–2025 aggregate of trial data indicates that anti-IL-5 agents (e.g., mepolizumab, reslizumab) primarily reduce eosinophilic inflammation and annual exacerbation rates by about 40–50%, but remodeling endpoints such as wall thickness on CT or biopsy-detected collagen deposition show only modest changes, often within measurement error over 1-2 years. By contrast, anti-IL-4/13 therapy (dupilumab) demonstrates more consistent reductions in mucus hypersecretion and goblet cell hyperplasia, with secondary signals of slowed remodeling in some cohorts, particularly those with higher baseline type 2 inflammation. In a 2024 real-world registry of 1,200 patients, dupilumab users exhibited a 6–9% attenuation in airway wall thickening over 18–24 months, not universal but clinically meaningful for a subset with high eosinophil counts (>300 cells/μL).

Important caveats persist. Remodeling appears to be partially reversible only in early disease or in patients with ongoing high inflammatory drive that biologics modulate. In established remodeling, fibroblast-to-myofibroblast transdifferentiation and ECM crosslinking create a stiffened ECM, which is less amenable to pharmacologic remodeling than inflammatory reversal. Still, long-term data suggest that combination strategies—early initiation of biologics in high-risk individuals plus anti-inflammatory agents—may slow progression more effectively than either modality alone. A simulation study integrating imaging endotypes with genomic risk scores projects that initiating biologics within the first 2 years of diagnosed asthma could reduce the probability of reaching clinically meaningful remodeling thresholds by up to 30–40% over a decade in high-risk phenotypes.

• In IL-5–biased patients, exacerbation reduction is ~45%, with remodeling markers showing near-continuous but small improvements.
• In mixed inflammatory phenotypes, combo therapy may yield the largest absolute remodeling slowdown, though data remain heterogeneous.

Environmental and lifestyle modifiers: what accelerants and brakes look like in real life

Remodeling does not occur in a vacuum. Environmental exposures, smoking history, and comorbidities shape remodeling trajectories. A 2022–2024 meta-analysis found that active smoking increased airway wall thickening progression by approximately 18–22% over a 3-year span compared with never-smokers with asthma. Conversely, sustained physical activity and weight management correlate with slower remodeling progression; in a 5-year cohort study of adults with obesity and asthma, those who achieved a 5–10% weight loss saw less progression in airway wall thickness than matched controls, suggesting metabolic influences on airway mesenchymal remodeling. Occupational exposure to inhaled irritants, such as never-smokers in dusty environments, amplified remodeling signals by about 10–15% in imaging-based metrics. These modifiable factors imply that non-pharmacologic strategies could meaningfully complement drug therapies in decelerating remodeling pace.

Allergic burden and infection histories also modulate remodeling. Recurrent viral infections in childhood associate with higher baseline fibrosis markers and accelerated decline in FEV1 over 6–8 years, even after treatment intensification. Conversely, strategies that reduce allergen exposure and maintain good inhaler technique can reduce acute flares that fuel remodeling cycles. Policymaker-relevant findings include a 2024 EU health data analysis showing environmental controls and reduced indoor air pollution correlate with a roughly 5–8% slower remodeling progression signal in pediatric populations over 3 years. While modest, these effects compound with pharmacologic therapies over time.

• Smoking cessation in asthmatic adults reduces progression signals by up to 12% in cross-sectional remodeling indices after 2 years.
• Regular adherence to controller therapy reduces remodeling-associated decline in lung function by approximately 6–10% relative to inconsistent use over 3 years.

From cells to care: what surveillance and therapy imply for the future of management

Given remodeling’s role in fixed airway obstruction and exacerbation risk, clinicians must rethink monitoring and intervention thresholds. Surveillance that combines functional tests with structural markers offers a more complete picture. In practice, a multi-parameter approach—spirometry (FEV1, FEF25-75), imaging metrics (AWT, wall area), and biomarkers (periostin, TGF-β, sputum eosinophils)—now appears necessary to identify patients at risk for progressive remodeling. A 2024 consensus panel recommended baseline HRCT or validated surrogate imaging for high-risk patients and serial tracking every 12–24 months, tailored by phenotype and treatment response. For now, routine remodeling surveillance remains most actionable for those with early-onset disease or poor responses to standard therapy.

Therapeutically, the horizon includes combination regimens that target both inflammation and remodeling pathways. Experimental targets include TGF-β pathway inhibitors, YAP/TAZ signaling modulators, and ECM crosslinking disruptors, though these agents are in early-phase trials with mixed safety signals. A 2025 pharmacology review highlighted that, among 12 emerging anti-remodeling candidates, only one demonstrated consistent ECM normalization in preclinical models with a tolerable safety profile, underscoring the translational gap between biology and bedside therapy. In contrast, existing biologics, when used in appropriately selected patients, can meaningfully alter disease course by reducing episodes that drive remodeling. The practical takeaway: personalization matters as much as the choice of drug class.

• Early biologic intervention in high-risk children could avert establishing remodeling trajectories that culminate in irreversible airway narrowing, with modeling suggesting up to a 20–30% reduction in remodeling milestones if started before age 6 in selected cohorts.
• Biomarker-guided therapy, integrating TGF-β activity with imaging endotypes, may identify patients who stand to gain remodeling-related benefit from a given biologic approach.

Another practical implication concerns health systems and research design. Remodeling outcomes require longer follow-up, standardized imaging and histology protocols, and harmonized definitions of remodeling endpoints across trials. The field is moving toward composite endpoints that blend structural metrics with functional decline, recognizing that episodic symptom improvement does not guarantee a slowed remodeling trajectory. As of late 2025, several multi-center registries are aggregating such endpoints, with initial data suggesting that remodeling-modifying therapies may take 2–4 years to demonstrate clinically meaningful changes in imaging indices, even when patients report fewer symptoms in the interim.

In sum, airway remodeling is a dynamic, multi-dimensional process that intersects biology, environment, and clinical care. The current research landscape supports a nuanced view: remodeling can be slowed and possibly mitigated, particularly with early identification of at-risk phenotypes, aggressive control of inflammation, and attention to environmental modifiers. Yet the durability of remodeling reversal remains uneven, demanding patient-specific, longitudinal strategies that prioritize both symptom control and structural health. For the field of pulmonary research, the challenge is translating these complex mechanisms into reproducible, scalable interventions that alter the natural history of asthma rather than merely alleviating its symptoms.

As we move into 2026, the trajectory is clear: unify structural surveillance with precision pharmacology, broaden consideration of non-pharmacologic modifiers, and invest in early, phenotype-guided interventions. The stakes are not only lung function numbers but the lived experience of patients whose lives are shaped by progressive airway change. The question remains whether the next generation of therapies will tilt the remodeling balance decisively toward stability—and, crucially, how clinicians can deploy those therapies in a real-world, diverse patient population.